†Department of Biomedical Engineering, The Ohio State University, Columbus, Ohio 43210, United States.
‡Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio 43210, United States.
ACS Nano. 2015 Jun 23;9(6):5725-40. doi: 10.1021/nn506928p. Epub 2015 May 29.
Tumor reinitiating cancer stem-like cells are responsible for cancer recurrence associated with conventional chemotherapy. We developed a doxorubicin-encapsulated polymeric nanoparticle surface-decorated with chitosan that can specifically target the CD44 receptors of these cells. This nanoparticle system was engineered to release the doxorubicin in acidic environments, which occurs when the nanoparticles are localized in the acidic tumor microenvironment and when they are internalized and localized in the cellular endosomes/lysosomes. This nanoparticle design strategy increases the cytotoxicity of the doxorubicin by six times in comparison to the use of free doxorubicin for eliminating CD44(+) cancer stem-like cells residing in 3D mammary tumor spheroids (i.e., mammospheres). We further show these nanoparticles reduced the size of tumors in an orthotopic xenograft tumor model with no evident systemic toxicity. The development of nanoparticle system to target cancer stem-like cells with low systemic toxicity provides a new treatment arsenal for improving the survival of cancer patients.
肿瘤起始癌症干细胞样细胞是导致与常规化疗相关的癌症复发的原因。我们开发了一种阿霉素包封的聚合物纳米颗粒表面修饰壳聚糖,能够特异性靶向这些细胞的 CD44 受体。该纳米颗粒系统被设计为在酸性环境中释放阿霉素,当纳米颗粒定位于酸性肿瘤微环境中以及被内化并定位于细胞内体/溶酶体中时,就会发生这种情况。与使用游离阿霉素相比,这种纳米颗粒设计策略使阿霉素的细胞毒性提高了六倍,从而消除了存在于 3D 乳腺肿瘤球体(即乳腺球体)中的 CD44(+)癌症干细胞样细胞。我们进一步表明,这些纳米颗粒在没有明显全身毒性的原位异种移植肿瘤模型中减少了肿瘤的大小。针对具有低全身毒性的癌症干细胞样细胞的纳米颗粒系统的开发为改善癌症患者的生存率提供了新的治疗手段。